IDLDX — IDL Diagnostics AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK78.32m
- SEK55.16m
- SEK53.11m
Brief: Arocell Informs About FDA Feedback Regarding 510(K) Application
Brief: Arocell Expands Arocell TK 210 Elisa In Europe
Brief: AroCell Q1 Loss Before Financial Items Widens To SEK 6.08 Mln
Brief: Arocell Announces Takeover Offer For IDL Biotech
Brief: AroCell: FDA Resumes Review Of AroCells 510(k) Submission
Brief: AroCell: Study Supports That TK1 Can Predict Death In Prostate Cancer
Brief: Arocell Says FDA Informs That Review Of Arocells 510(k) Submission To Resume At Latest April 15
Brief: Arocell Q4 Loss Before Items Flat At SEK 6.0 Mln
Brief: Arocell Appoints New CEO
Brief: Arocell Q3 Loss Before Financial Items Widens To SEK 6.4 Mln
Brief: Arocell AB Says Dialogue Has Been Held With FDA Regarding 510(K) Submission That Co Submitted On May 26
Brief: AroCell Gets Decision To Grant For European Patent Application
Brief: Arocell Q2 Oper Loss Widens To SEK 6.2 Mln
Brief: Arocell Announces New Collaboration With University Of Rome La Sapienza
Brief: Arocell Gets Patent Approved In Japan
Brief: AroCell Gets Notice Of Allowance For European Patent Application
Brief: AroCell: TK1 Can Be Used For Early Detection Of Therapy Response In Breast Cancer Treatment
Brief: Arocell Q2 Loss Before Financial Items Narrows To SEK 4.9 Mln
Brief: AroCell Signs Distributor Agreement In USA And Canada